Research programme: Src-ND2 inhibitors - NoNO
Latest Information Update: 26 Oct 2016
At a glance
- Originator NoNO
- Class Anti-inflammatories
- Mechanism of Action Protein-protein interaction inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Neuropathic pain
Most Recent Events
- 26 Oct 2016 Preclinical trials in Inflammation in Canada (unspecified route)
- 26 Oct 2016 Preclinical trials in Neuropathic pain in Canada (unspecified route)